Potential of 바카라 에볼루션 strategy highlighted for EGFR-mutated, MET-amplified non-small cell lung cancer
[by Ji, Yong Jun] Abion announced on April 22 that it will present supplementary data at the upcoming American Association for Cancer Research (AACR) Annual Meeting, including data on drug-drug interactions (DDI) observed with the co-administration of ‘vabametkib (development code: ABN401),’ a hepatocyte growth factor receptor (MET) inhibitor, and ‘lazertinib,’ a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The AACR conference is scheduled to take place in Chicago, Illinois, USA, from April 25 to 30 (local time).
EGFR mutations are frequently observed in patients with non-small cell lung cancer (NSCLC). Although EGFR 바카라 에볼루션s targeting these mutations demonstrate high therapeutic efficacy, resistance inevitably develops in many cases, involving amplification of the MET gene, which enables cancer cells to bypass EGFR inhibition and continue proliferating. According to the company, MET amplification is observed in up to 26% of patients with EGFR mutations.
Abion previously reported preclinical research findings on a patient-derived xenografts (PDX) model characterized by both EGFR mutations and MET amplification. In this model, the combination 바카라 에볼루션 of vabametkib and lazertinib achieved a ‘tumor growth inhibition (TGI)’ rate of 96.6%, demonstrating a high anticancer effect compared to mono바카라 에볼루션.
In the additional drug interaction (DDI) analysis to be presented at this year’s AACR, the potential for interaction with Lazertinib was found to be minimal, confirming that there is no significant concern regarding altered efficacy or side effects when the two agents are administered in 바카라 에볼루션.
Looking ahead, the clinical application of this combination 바카라 에볼루션 is anticipated to offer significant advantages in terms of administration safety and ease of drug management. Given that drug-drug interactions are a major limiting factor in the development of combination treatments, these findings are considered a key indicator highlighting the distinctiveness of the combination 바카라 에볼루션.
The findings also indicate that the combination of vabametkib and an EGFR TKI may represent a novel treatment option for patients with advanced NSCLC with EGFR mutations along with MET amplification or overexpression, particularly in cases where the disease has progressed following treatment with third-generation EGFR TKIs. Currently, the company is conducting Phase 2 clinical trials in Korea, the United States, Taiwan, and other countries to assess the efficacy and safety of the combination 바카라 에볼루션.
“We are committed to ensuring the success of the Phase 2 clinical trials for the combination 바카라 에볼루션, especially as it has attracted great interest from major global pharmaceutical companies at international events. If the trials prove successful, the 바카라 에볼루션 has the potential to become a ‘best in class’ treatment with the highest efficacy in its category,” an Abion official said. “Building on the results of the Phase 2 clinical trial, we intend to accelerate the approval process for the mono바카라 에볼루션 as well. Finalizing a global licensing agreement is also a priority and will process swiftly.”